Bococizumab is a novel anti-PCSK9 antibody effectively developed to treat hypercholesterolemia. This therapeutic agent functions through the PCSK9 protein, a critical regulator of cholesterol amounts. By inhibiting the https://www.targetmol.com/compound/bococizumab